课题基金 / 基金详情

Respiratory Dysfunction in an Optineurin knock out ALS mouse model

Respiratory Dysfunction in an Optineurin knock out ALS mouse model
Optineurin 敲除 ALS 小鼠模型中的呼吸功能障碍
批准号:
9978360
负责人:
Mai ElMallah
金额:
$44.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-01 至 2022-09-30

项目摘要

项目成果

Mai ElMallah的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
7. PROJECT SUMMARY/ABSTRACT Amyotrophic Lateral Sclerosis (ALS) is a devastating and fatal neurodegenerative disease with no current cure. Focal weakness eventually progresses to global muscle weakness and paralysis, but the exact etiology of these events remains unknown. Many patients die when they ultimately succumb to inadequate ventilation, hypoxia, and respiratory failure. Recently, the gene for optineurin (OPTN) was found to be associated with neurodegeneration in ALS. Patients with OPTN mutations show an onset of ALS from 30 to 60 years of age and have a slowly progressive disease before they eventually die of respiratory failure. The etiology of OPTN deficiency induced respiratory failure remains unknown and will be a focus of Aim 1 of this application. In addition, in Aim 2, we will look at the impact of hypoxia (or low oxygen levels) on disease initiation and progression. In ALS, impaired breathing due to progressive weakness of the respiratory muscles leads to chronic intermittent hypoxia. However, prior to diagnosis, we propose that hypoxia may also play a role in triggering the disease onset and exacerbating motor weakness in OPTN deficient patients. At the cellular level, hypoxia induces mitochondrial degradation, activates autophagy and induces cell death. Interestingly, OPTN regulates mitochondrial degradation, autophagy and cell death. Since OPTN is essential in regulating autophagy, we propose that in the absence of OPTN, the effects of chronic intermittent hypoxia (CIH) will be amplified and will result in protein aggregation and cellular disruption in respiratory motoneurons. This disruption will further exacerbate breathing impairment. Thus, the fundamental hypothesis driving this proposal is that OPTN deficiency impairs respiratory function, and exposure to CIH triggers early disease onset and accelerates respiratory pathology. In order to test our hypothesis, we will use OPTN knock out mice (Optn-/-) generated by Henry Tseng (co-I). Similar to pathology experienced by ALS patients, these mice exhibit deficits in balance, coordination, and motor impairment that progressively deteriorates with age. Optn-/- mice provide an important opportunity and an ideal tool to study stress-dependent mechanisms that exacerbate neurodegeneration and respiratory function in ALS. Two specific aims will be accomplished using the Optn-/- mouse model: Aim 1: To identify the impact of OPTN deficiency on respiratory function and respiratory motoneurons, nerves, and muscle in ALS and Aim 2: To assess the impact of CIH on disease onset and progression in OPTN deficiency. The proposed experiments address a comprehensive evaluation of respiratory function including spontaneous breathing and respiratory nerve output, as well as biochemical and histological assessment of respiratory motor units. This R21 proposal will combine the respiratory physiology and ALS mouse model experience of the PI (ElMallah), with the neurobiology and optineurin experience of the co-I (Tseng). Project Summary/Abstract Page 1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted Therapy for Pompe Disease
  • 批准号:
    10621268
  • 项目类别:
  • 资助金额:
    $34.54万
  • 财政年份:
    2019
  • 负责人:
    Mai ElMallah
  • 依托单位:
Targeted Therapy for Pompe Disease
  • 批准号:
    10202684
  • 项目类别:
  • 资助金额:
    $34.54万
  • 财政年份:
    2019
  • 负责人:
    Mai ElMallah
  • 依托单位:
Targeted Therapy for Pompe Disease
  • 批准号:
    10017695
  • 项目类别:
  • 资助金额:
    $34.84万
  • 财政年份:
    2019
  • 负责人:
    Mai ElMallah
  • 依托单位:
Targeted Therapy for Pompe Disease
  • 批准号:
    10402842
  • 项目类别:
  • 资助金额:
    $34.54万
  • 财政年份:
    2019
  • 负责人:
    Mai ElMallah
  • 依托单位:
海外基金